關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Global Business NewsGlobal Business News

目前Global Business News文章數, 共 20913 篇 ,以下為 385 - 408 篇 訂閱此列表,掌握最新動態
Geek+ Collaborates with Toll Group to Launch its First Robotics Sorting Warehouse in Korea

SEOUL, South Korea, April 15, 2024 /PRNewswire/ -- Geekplus, the global leader in mobile robot and smart logistics solutions, has launched an advanced automated warehouse with Toll Group, its first collaboration with the prominent global logistics company. The warehouse, which spans an area equivalent to four football fields, can store up to 300,000 inventory items. Geekplus sortation robots have been deployed by Toll Group in a South Korean facility. "We are thrilled to deliver a competitive edge to Toll through the seamless integration of robotic automation into their supply chain," said Stephen Kim, Sales Director of Geekplus Korea. "This is the first Geekplus partnership with Toll Group, and we will continue to explore future opportunities jointly. We anticipate empowering Toll to expand the applications of mobile order fulfilment robots and replicate the success of this project in the future." At Toll Group's newest site at Baeksa, more than 60 robots seamlessly streamline the sortation operations, resulting in a 70% increase in productivity and sorting efficiency in support of e-commerce, retail and omnichannel fulfilment for their retail customers. This remarkable improvement has led to substantial cost savings associated with time and labor, enabling Toll Group to provide faster e-commerce order delivery, as well as real-time tracking and traceability for enhanced customer satisfaction. "The investment reflects Toll's commitment to innovation and is part of our broader strategy to grow in key Asian markets by providing our customers with the very latest in warehouse automation technology," said Dongseop Yoon, Senior Business Development Executive at Toll. "As our business grows, Geekplus' sorting system has enabled us to manage increasing volumes quickly and efficiently." Watch the robots to and see how this collaboration sets a strong foundation for Geekplus' continued contributions to the transformation of smart logistics. About Geekplus Geekplus is a global leader in mobile robotics technologies. We develop innovative robotics solutions for order fulfilment. Geekplus has offices in the United States, Germany, the United Kingdom, Japan, South Korea, Mainland China, Hong Kong SAR, and Singapore. About Toll Group At Toll, we do more than just logistics - we move the businesses that move the world. Our 16,000 team members can help solve any logistics, transport or supply chain challenge – big or small. We have been supporting our customers for more than 130 years. Today, we support more than 20,000 customers worldwide with 500 sites in 27 countries, and a forwarding network spanning 150 countries. We are proudly part of Japan Post.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 84 加入收藏 :
VanceAI Generates AI Fashion Models and Upscales Them to High Resolution

HONG KONG , April 15, 2024 /PRNewswire/ -- VanceAI.com upgrades AI Fashion Model Generator to generate suitable models for clothes. E-commerce sellers can upload images of clothing worn on mannequins or on real individuals after which AI Fashion Model Generator will replace the models with more attractive ones and generate more aesthetically pleasing backgrounds. Then users can preview the effect of clothes on different models without any effort. VanceAI Image Upscaler helps to further upscale generated model images to strengthen the effect. AI Fashion Model Generator Previews Clothes on AI Models Online Fashion e-commerce is a highly competitive industry where the presentation of clothing plays a pivotal role in attracting and engaging customers. Traditional methods of showcasing clothes on mannequins or real individuals come with inherent challenges, from time-consuming photoshoots to limited model availability. VanceAI's AI Fashion Model Generator addresses these pain points, offering a revolutionary approach to clothing presentation. More specifically, fashion retailers, independent designers, and marketers looking to streamline their product presentation workflow can take advantage of AI Fashion Model Generator. This tool empowers them to showcase clothing with stunning visuals, eliminating the need for extensive and costly photoshoots. It is particularly beneficial for businesses aiming to maintain a consistent and appealing online presence in the competitive fashion e-commerce landscape. VanceAI Fashion Model Generator offers the most convenient and affordable choice for users. They can go to its product webpage to find basic information on AI Fashion Model Generator, such as what AI Fashion Model Generator is and how it works. After entering the workspace, they can upload a clothing photo, and then AI will automatically process the image. Seeing the Generate button, they can click it to generate lifelike models wearing clothes. AI Fashion Model Generator offers ample templates, such as body ages, sizes and skin tones in Product Image Design Workspace. It enables users to customize AI fashion models with the templates or text as well. Then users can better preview the effect of clothes on different models. The model generator gets rid of time-consuming and expensive photoshoots, accelerating the process of clothing presentation. It also ensures a consistent and professional look across the entire product catalog, contributing to a visually appealing and trustworthy online shopping experience. Sellers can effortlessly experiment with different fashion models, catering to diverse customer preferences. This adaptability enhances the versatility of product presentations. AI Image Upscaler Upscales Generated Model Images by up to 8x or 40x VanceAI Image Upscaler can also be used to upscale generated model images by AI Fashion Model Generator. Online sellers tend to use high-quality images to enhance engagement. AI Fashion Model Generator is able to generate clear model images, but sometimes their effect still needs to be enhanced, which explains why upscaling images is important. When users get model images and want much clearer ones, they may turn to AI Image Upscaler. They only need to upload the image not clear, choose a model and a scale from 2x to 40x, and click on Start to Process. After a few seconds, AI will show upscaled images. If users just want to enhance image quality while not changing image size, AI Image Enhancer is an ideal choice. If users want to highlight and sharpen the details, AI Image sharpener is the choice.  About VanceAI VanceAI, an AI photo enhancement, generation and editing tools provider, offers solutions for photo enhancement, generation and editing. Apart from generating AI models for clothes, VanceAI also opens an AIGC page where users can find more AI generation tools including AI Image Generator creating an image from text online. Toongineer Cartoonizer and VansPortrait have revolutionized the AIGC landscape, introducing one-click cartoon conversion and tackling the complexities of transforming images into lifelike pencil sketches. The AIGC suite also encompasses AI Face Generator, AI Portrait Generator, and VTuber Maker, each contributing to unique aspects of graphic content creation. Beyond these achievements, VanceAI extends its commitment to user empowerment with a suite of specialized tools. The duo of BGremover and VanceAI Background Generator addresses the e-commerce industry's challenges by revolutionizing product image presentation. BGremover's precision background removal, with enhanced capabilities in dealing with details like hair or edges, leads to more authentic portrait cutouts. Transitioning to VanceAI Background Generator, e-commerce professionals benefit from an extensive library of templates and styles for contextually relevant product backgrounds. PNG Maker effortlessly helps create transparent PNG images online in a single click, and AI Passport Photo Maker streamlines passport photo generation. For more information, please visit VanceAI official websites.Option 1: VanceAI Official Website for EnglishOption 2: VanceAI Official Website for DeutschOption 3: VanceAI Official Website for FrançaisOption 4: VanceAI Official Website for Japanese ContactsCompany: VanceAI TechnologyWebsite: https://vanceai.com/Email: marketing@vanceai.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 88 加入收藏 :
Driving automation: tesa and ABB join forces to showcase innovative hole covering automation technology in Japan

tesa and ABB demonstrate tesa® ProSeal cartridge-based tape applicator to Japanese and Korean Automotive OEMs. tesa® ProSeal is the next generation, fully automated solution to cover holes within automotive car bodies. With its unique cartridge system, tesa® ProSeal maximizes process efficiency and reduces liner waste. SHIZUOKA, Japan, April 15, 2024 /PRNewswire/ -- tesa, an international manufacturer of innovative adhesive tapes and self-adhesive product solutions, and ABB, a technology leader in electrification and automation system integrator, are giving a live demonstration of the tesa ProSeal cartridge-based tape applicator for fully automated hole covering. The event will take place over five days from 15 to 19 April, 2024. tesa and ABB are inviting Japanese and Korean automotive OEMs to ABB's technical center in Shimada City, Japan, to demonstrate the most advanced automation technology for the hole covering tape application process in the automotive industry. tesa® demonstrates ProSeal hole covering automation Innovative ecosystem for maximum efficiency and waste reduction tesa® ProSeal is the unique ecosystem that offers significant improvements in production efficiency and flexibility, while achieving waste reduction in automotive hole covering application. The cartridge is compatible with different materials and/or dimensions of tesa® hole cover patches, and the robot automatically switches the cartridge in 10 seconds to apply the appropriate patches, minimizing the complexity of the process and the capital investment in automated equipment. Moreover, tesa collects the used cartridge and replenishes the cartridges with new patches to minimize packaging materials and reduce liner waste. With production innovations like these, tesa supports customer to achieve their sustainability targets as well as reduces operation costs with fully automated processes. "We are proud to collaborate with ABB to introduce tesa® ProSeal, our innovative hole-covering automation technology, to the automotive industry in Asia Pacific," said Andreas Gunnestrand, President & Regional Manager, tesa Asia Pacific. "This partnership highlights our commitment to providing cutting-edge solutions that not only drive automation, but also contribute to sustainability and waste reduction in the automotive industry." "This strategic collaboration exemplifies ABB's commitment to pioneering innovative robotics and automation solutions to transform industries and future-proof business," says Takashi Asari, head of ABB's Robotics & Discrete Automation division, Japan. "We are also introducing our new Omnicore™ robot controller, which has market-leading motion control capabilities and reduces power consumption by up to 20 percent, making manufacturing more accurate, efficient and sustainable." tesa has a long-standing partnership with the automotive industry, providing intelligent solutions that contribute to areas such as automation and e-mobility. Its innovative self-adhesive tape solutions and application process technology play a critical role in improving manufacturing processes and product performance for automotive OEMs and their suppliers worldwide. Through continuous innovation and collaboration, tesa remains committed to driving the automotive industry towards a more efficient, sustainable, and technologically advanced future. Get more information about tesa® ProSeal here. About tesa: As a multinational company, tesa develops innovative adhesive tapes and self-adhesive product solutions for various industries, commercial customers, and end consumers. There are already more than 7,000 tesa adhesive solutions that help improve the work, products or lives of our customers. Today, the focus is on sustainability and energy-saving processes. tesa invests in the development of environmentally friendly products and solvent-free manufacture processes as well as in the use of renewable energy sources at its locations. About ABB: ABB is a technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. The company's solutions connect engineering know-how and software to optimize how things are manufactured, moved, powered and operated. Building on over 140 years of excellence, ABB's more than 105,000 employees are committed to driving innovations that accelerate industrial transformation. www.abb.com   Up close of tesa® ProSeal hole covering solution tesa® ProSeal hole covering in action

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 90 加入收藏 :
ENDLESS MOUNTAINS: Spanning Mountains and Seas--An Exhibition of Art and the Tang Poetry Road

OSAKA, Japan, April 15, 2024 /PRNewswire/ -- ENDLESS MOUNTAINS: Spanning Mountains and Seas—An Exhibition of Art and the Tang Poetry Road opened on April 13 at the Osaka Culturarium at Tempozan, Japan. It was hosted by the China Academy of Art (CAA), the Chinese Consulate General in Osaka, and the China Academy of Building Research (CABR). The exhibition unfolded with one year to go before the World Expo 2025 opens in the key port city of Osaka where the "China-Japan Maritime Poetry Road" started, echoing the theme of the China Pavilion: "Jointly Build a Community of Life For Man And Nature—Future Society of Green Development" in the spirit of "mutual learning between civilizations". Across the waters from the Expo 2025 Osaka venue, the event gathers 22 Chinese and Japanese artists for a Tang poetry journey with the audiences in the context of a new era. The exhibition is a review of cultural and historical legacies that still have a positive impact today, a showcase of civilizations that have been thriving for centuries, and a revelation of advances that many generations have made, as the "Tang Poetry Road" is a geographical road connecting mountains and seas, and most importantly, a road linking poetic souls. Derived from this road is the "China-Japan Maritime Poetry Road"— the road of seeking Dharma for monk-poets in ancient times; the road of poetic diplomacy for the envoys of the two nations; the road of communication for Chinese literati and ancient Japanese missions to the Tang Dynasty; the road of the dissemination of Chinese poetry to Japan as an extension of the Road of Tang Poetry in Eastern Zhejiang; and the road of people-to-people exchanges through seas. The route witnessed the long history of cultural exchanges between China and Japan, demonstrating the deep friendship that transcends physical boundaries and eras. The exhibition links the Road of Tang Poetry in Eastern Zhejiang and the China-Japan Maritime Poetry Road, displaying over 70 excellent art works. The works include Tang Poetry Road executed by a CAA team of teachers and students led by Prof. Lin Haizhong, Chaos Script of Hanshan's Poetry created by Wang Dongling specially for this exhibition, Zhuo Hejun's watercolor titled High Spring into Dreams, etc. The exhibition lasts from April 13 to 27.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 88 加入收藏 :
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90% SYDNEY, April 15, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites. The XanaMIA trial is a double-blind placebo-controlled randomized trial design which will enrol 220 participants with mild to moderate AD and elevated levels of plasma pTau. The trial measures the effects of a Xanamem® 10 mg daily dose versus placebo on safety and its ability to preserve cognition and function over a 36-week treatment period. The primary endpoint is a cognitive test battery comprising seven different digital assessments (previously, Xanamem benefits on cognition were observed in three separate placebo-controlled trials including an initial study in AD). A key secondary endpoint is the Clinical Dementia Rating – Sum of Boxes scale (CDR-SB), a validated combined cognitive and functional measure, used by the FDA and many companies as a primary or secondary endpoint for regulatory approval. Previously, in an analysis of biomarker-positive patients with mild AD treated with Xanamem, clinically significant benefits were seen on cognition and the CDR-SB endpoint. A variety of other secondary endpoints include the Amsterdam Activity of Daily Living scale, which measures the ability to perform everyday tasks.  The trial has commenced at thirteen Australian sites and will subsequently expand to the USA. An interim analysis is planned for mid-2025 when approximately 100 patients reach 24 weeks of treatment, with final results anticipated in H1 2026. Dr Steven Gourlay, Actinogen's CEO said: "We are very pleased to announce the first patient treated in our phase 2b trial in patients with Alzheimer's disease. Based on encouraging safety and clinical activity seen in multiple prior trials of Xanamem, and a strong scientific rationale for reducing brain cortisol levels, we are confident that the trial will confirm clinically and statistically meaningful results." "This phase 2b trial is designed to confirm that Xanamem is a safe and effective new treatment for Alzheimer's disease and represents a major opportunity for patients and the Company." Actinogen awarded UK Innovation Passport for Xanamem Actinogen has also received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its application for an Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease. Key benefits of this approval include: Entry point to the ILAP which aims to accelerate time to market Linkage to a portfolio of activities through the product-specific creation of the Target Development Profile (TDP) in conjunction with the MHRA Opportunities for enhanced regulatory and other stakeholder input including from partner agencies such as the MHRA and National Institute for Health and Care Excellence (NICE). Dr Steven Gourlay, Actinogen's CEO said: "The MHRA's approval of the ILAP application validates our belief in Xanamem's unique and encouraging profile for the treatment of Alzheimer's disease. Following on from three prior trials showing promising activity, Actinogen's 220-person phase 2b trial in Alzheimer's is now underway and will report initial results in mid-2025." The next step in the ILAP process will be to commence development of the TDP. XanaCIDD phase 2a cognitive impairment and depression trial nears completion The XanaCIDD Phase 2a depression trial enrolment has surpassed 90% Full enrolment of approximately 160 patients is expected later in April Results to report in early Q3 2024 The XanaCIDD Phase 2a Depression trial is a six-week proof-of-concept, placebo-controlled, parallel group design trial in patients with persistent Major Depressive Disorder (MDD) and cognitive impairment. Xanamem 10 mg daily or placebo is added to the existing anti-depressant therapy, if being used. Therapeutic effects on cognition, measured using an "Attention Composite" of the computerized Cogstate Cognitive Test Battery are assessed as the primary endpoint (a composite of the One Back, Identification and Detection tests). Effects on depression are measured using the Montgomery-Asberg Depression Rating Scale. Previously, positive benefits on cognition were observed using the same Attention Composite endpoint in two independent, placebo-controlled trials of older, cognitively normal volunteers. About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health. Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making. Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer's Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments. Current Clinical Trials The XanaCIDD Phase 2a depression trial is a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 160 patients. Patients are evenly randomized to receive Xanamem 10 mg once daily or placebo, in some cases in addition to their existing antidepressant therapy, and effects on cognition and depression are assessed. The XanaMIA Phase 2b Alzheimer's disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of a pTau protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and effects on cognition, function and progression of Alzheimer's disease are assessed. Thus, Xanamem is being assessed in this trial for its potential effects as both a cognitive enhancer and a disease course modifier. About Xanamem Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing. Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The Company has studied 11β-HSD1 inhibition by Xanamem in more than 350 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in functional and cognitive ability in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem's therapeutic potential. Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical. Disclaimer This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. ® Xanamem is a registered trademark of Actinogen Medical Limited  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 88 加入收藏 :
SU Group Successfully Implements Virtual Call Center to Support Growth

HONG KONG, April 15, 2024 /PRNewswire/ -- SU Group Holdings Limited (Nasdaq: SUGP) ("SU Group" or the "Company"), an integrated security-related engineering services company in Hong Kong, today announced it has successfully implemented a Virtual Call Center ("VCC") to support its business growth and further expansion. The advanced system was customized to SU Group's technical specifications and will provide a superior experience to its customers and partners as well as increase their operational efficiency. SU Group has already rolled out access reducing wait times by an estimated 70% and saving an estimated 3,500 personnel hours. The VCC solution utilizes the cutting-edge mobile cloud technologies to digitally streamline the processing of emergency calls, preventive maintenance inquiries and service orders, thereby increasing workflow efficiency and saving significant operator time and expense. Moreover, customers also benefit from a faster response time, with increased readiness and clarity of information and communication. Future-proofing ensures that customer data can migrate whenever new features and enhancements are added to the VCC. SU Group's Chairman and CEO, Dave Chan, commented, "Businesses that provide a superior customer experience are typically the winners across all industries. Based on this fundamental truth, we are committed to delivering continuous improvements to serve our customers. We saw an important opportunity to work with an outside partner to develop and implement a customized Virtual Call Center, which provides a more efficient, end-to-end solution to our customers and partners. We believe this will give us an added competitive advantage as we continue to scale our business and drive revenue growth." About SU Group Holdings Limited SU Group (Nasdaq: SUGP) is an integrated security-related services company that primarily provides security-related engineering services, security guarding and screening services, and related vocational training services in Hong Kong. Through its subsidiaries, SU Group has been providing turnkey services to the existing infrastructure or planned development of its customers through the design, supply, installation, and maintenance of security systems for over two decades. The security systems that SU Group provides services include threat detection systems, traffic and pedestrian control systems, and extra-low voltage systems in private and public sectors, including commercial properties, public facilities, and residential properties in Hong Kong. For more information visit www.sugroup.com.hk. Forward-Looking Statements Certain statements in this press release are forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could" and similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to renew contracts with recurring customers; the Company's ability to accurately estimate risks and costs and perform contracts based on the Company's estimates; the Company's relationship with the Company's suppliers and ability to manage quality issues of the systems; the Company's ability to obtain or renew the Company's registrations, licenses, and certificates; the Company's ability to manage the Company's subcontractors; the labor costs and the general condition of the labor market; implementation of the Company's expansion plans and the Company's ability to obtain capital resources for planned growth; the Company's ability to acquire sufficient products and obtain equipment and services from the Company's suppliers in suitable quantity and quality;  the Company's ability to expand into new businesses, industries, or internationally and to undertake mergers, acquisitions, investments, or divestments; changes in technology and competing products; general economic and political conditions, including those related to the security-related engineering services industry; possible disruptions in commercial activities caused by events such as natural disasters, terrorist activities, political, economic, and social instability, and fluctuations in foreign currency exchange rates, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (the "SEC"), including the Company's most recently filed Annual Report on Form 20-F and its subsequent filings. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 88 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈